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A B S T R A C T
Background: Skeletal-related events (SREs; pathologic fracture [PF], spinal cord compression and radiation or
surgery to bone) are common complications of bone metastases or bone lesions and can impose a considerable
burden on patients and healthcare systems. In this study, the healthcare resource utilisation (HRU) associated
with PFs in patients with bone metastases or lesions secondary to solid tumours or multiple myeloma was
estimated in eight European countries.
Methods: Eligible patients were identiﬁed in Austria, the Czech Republic, Finland, Greece, Poland, Portugal,
Sweden and Switzerland. HRU data were extracted from hospital charts from 3.5 months before the index PF
(deﬁned as a PF preceded by a 6.5-month period without a SRE) until 3 months after the last SRE during the
study period. Changes from baseline in the number and duration of inpatient stays, number of outpatient visits
and number of procedures provided were recorded.
Results: Overall, 118 patients with PFs of long bones (those longer than they are wide, e.g. the femur) and 241
patients with PFs of other bones were included. Overall, HRU was greater in patients with long bone PFs than in
those with PFs of other bones. A higher proportion of patients with long bone PFs had multiple SREs (79.7%),
and more of their SREs were considered to be linked (73.4%) compared with patients with PFs of other bones
(51.0% and 47.2%, respectively).
Conclusion: The increased number and duration of inpatient stays for PFs of long bones compared with those
for PFs of other bones may be due in part to the requirement for complicated and lengthy rehabilitation in
patients with long bone PFs. Implementing strategies to delay or reduce the number of PFs experienced by
patients with bone metastases or lesions may therefore reduce the associated HRU and patient burden.
1. Introduction
Bone metastases aﬀect up to two-thirds of patients with advanced
solid tumours such as breast, prostate or lung cancer [1], and osteolytic
bone lesions are typical of multiple myeloma [2]. Individuals with bone
metastases or lesions are at a high risk of experiencing skeletal-related
events (SREs), including pathologic fractures (PFs), spinal cord
compression and radiation or surgery to bone [3–6].
PFs have commonly been reported in the placebo arms of clinical
trials that evaluated the eﬀect of bisphosphonates in patients with bone
metastases secondary to advanced cancers [7–9] and have been shown
to be detrimental to patients’ quality of life [10]. Statistically signiﬁcant
declines in the physical and emotional well-being of patients have been
reported after experiencing PFs [11]. Patients with PFs often require
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substantial orthopaedic treatment, including rehabilitation and sup-
portive care, such as pain relief, and therefore utilise considerable
healthcare resources. Furthermore, the occurrence of PFs has been
correlated with reduced survival rates in patients with bone metastases
[12].
Several studies worldwide have revealed that HRU and costs
associated with SREs, including PFs, in patients with bone metastases
or lesions are substantial [13–16]. However, these studies have focused
either on single countries or on small numbers of European countries.
Increasing healthcare providers’ knowledge of the HRU associated with
PFs in patients with bone metastases or lesions in Europe would
highlight the potential economic value of using treatments that prevent
or delay SREs. Such treatments may also reduce HRU and maintain
patients’ quality of life. This study aimed to estimate the HRU
associated with PFs in patients with bone metastases secondary to
solid tumours or lesions secondary to multiple myeloma in eight
European countries.
2. Methods
This was a multinational, retrospective study to assess hospital-
related HRU associated with PFs in patients with bone metastases or
lesions from Austria, the Czech Republic, Finland, Greece, Poland,
Portugal, Sweden and Switzerland. Patients eligible to participate in the
study were aged 20 years or older, had bone metastases secondary to
breast, lung or prostate cancer, or bone lesions due to multiple
myeloma. Patients also had to have experienced an index PF (deﬁned
as a PF preceded by a SRE-free period of at least 6.5 months) during
the study period (from 1 July 2004 to 1 July 2009) to be included.
Exclusion criteria included current enrolment or previous participation
in a denosumab clinical trial, death less than 2 weeks after the index PF
and patient chart data of insuﬃcient quality. Relevant patient charts
were identiﬁed at each site from electronic or paper patient lists using
the International Classiﬁcation of Diseases (ICD) Ninth Revision (ICD-
9) and Tenth Revision (ICD-10) codes. Data from consecutive patient
charts for those fulﬁlling the inclusion criteria and not meeting the
exclusion criteria were captured during the study period. The patient
chart with the most recent PF was analysed ﬁrst (even if this is not the
most recent Index SRE), then the second most recent was analysed (i.e.
systematically in reverse consecutive order) until the planned number
of PFs were documented on a country level.
According to European legislation for this type of retrospective
research, informed consent is generally not required. However, it was
provided when speciﬁcally requested by local authorities or the
institution. This study was approved by oﬃcial government institutions
and ethics committees, where required.
2.1. PF data collection
PFs were grouped into those aﬀecting long bones (i.e. bones that are
longer than they are wide, such as the femur) or those involving other
bones. Long bone fractures are usually major clinical events, whereas
fractures of some other bones may be asymptomatic and may be
discovered only by routine bone scanning. In this study, all PFs were
symptomatic but the HRU for these fracture types may diﬀer. Based on
epidemiology and feasibility studies, the target number was 10 patients
with at least one PF of a long bone and 30 patients with at least one PF
of other bones for each participating country. In addition to HRU data,
patients’ baseline demographics and disease characteristics were
documented.
2.2. HRU attribution
Retrospective HRU data were collected from patient charts during
the study period. For patients who experienced only the index PF
during the study period, data were extracted from hospital charts for a
period beginning 3.5 months before and ending 3 months after the
index PF [17] (Fig. 1a). In order to attribute HRU in patients with
multiple SREs, it was necessary to set a diagnostic window. In line with
a previous study [18], a period of 3 months starting 3.5 months before
the index PF was used to establish baseline HRU, and a 14-day (2
week) period immediately before the index PF was used to estimate any
diagnostic HRU [18]. For patients with multiple SREs, the data-
extraction period was extended until 3 months after the last SRE that
the patient experienced during the study period (Fig. 1b). There was no
limit to the number of SREs included in the period following the index PF.
To ensure lack of carry-over of HRU from a previous SRE that occurred
before the 3.5-month period immediately preceding the index PF, a clean
window of an additional 3 months without a SRE was required.
If multiple SREs were present at the same anatomical site and
occurred within a 21-day window, they were considered to be linked
and the total HRU was attributed to the index PF. In cases in which
SREs occurred at the same anatomical site but outside the 21-day
window, or at diﬀerent anatomical sites, the SREs were considered to
be unlinked and HRU was attributed to the appropriate SRE type
following chart review by an expert panel. Patients could experience
several linked and/or unlinked SREs simultaneously.
Primary HRU outcome measures were: the number and duration of
inpatient stays (overall and by type of hospital unit); the number of
outpatient visits (overall and by healthcare provider type); the number
of day-care hospital visits (visits to day-care centres were made by
patients who required more prolonged treatment or investigations than
outpatients, but who did not require an overnight stay); the number of
emergency room visits; and the number and types of procedures
provided. The proportion of patients receiving bisphosphonate medica-
tions at baseline and post-SRE (and the dose frequency) was recorded.
2.3. Statistical analyses
To estimate HRU associated with an index PF, the following
calculation was used.
Estimate of HRU associated with PF
= HRU recorded during post−PF period
+ HRU during diagnosis period
–HRU recorded during the baseline perioda
aAdjusted to allow for the diﬀerent lengths of the periods.
Statistical analyses were descriptive in nature; data are presented as
mean (standard deviation [SD]), because this better describes the total
HRU for the study population.
3. Results
3.1. Patients
In total, 118 patients with long bone PFs and 241 patients with PFs
of other bones were included. The baseline demographics of partici-
pants were generally consistent across all countries; however, the mean
age of patients with PF of long bones was higher in Finland (74.5 [SD
4.2] years; n=8) and Sweden (75.8 [SD 7.4] years; n=9) compared with
the other countries (range 61.5–68.9 years) (Table 1). Overall, the most
common cancer types were breast cancer (long bones 37.3%; other
bones 32.4%) and multiple myeloma (long bones 23.7%; other bones
40.7%) (Tables 1 and 2). The mean time since initial diagnosis of bone
metastases or lesions was approximately 1 year in both patients with
long bone PFs and those with PFs of other bones. The mean duration of
follow-up was similar for patients with long bone PFs (3.2 months; SD
1.2 months) and other bone PFs (3.3 months; SD 1.2 months). Overall,
the most common fractures aﬀecting long bones were those of the
femur (58.5%) and humerus (32.2%) (Table 3). Fractures of the
vertebrae were the most common fracture type in those with PFs
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aﬀecting other bones (66.7% overall; thoracic vertebrae 40.2%; lumbar
vertebrae 23.2%; cervical vertebrae 3.3%) (Table 4). Retrospective
review of those patients who had a long bone or other bone PF, 28.0%
(n=33) and 25.3% (n=61), respectively were receiving a bisphospho-
nate at baseline. After a SRE, the number of patients receiving a
bisphosphonate was 61.9% (n=73) in those patients with a long bone
PF and 69.3% (n=167) in those patients with a PF of other bones. The
most commonly used bisphosphonate was zoledronic acid (Tables 5
and 6).
3.2. SREs in patients with PFs
In the long bone PF group, more patients had multiple SREs than
Fig. 1. Study design and data collection for patients with one SRE (a) and multiple SREs (b). (a) To ensure lack of carry-over of HRU from a previous SRE that occurred before the 3.5-
month period preceding the index PF, a clean window of an additional 3 months without a SRE was required. (b) For multiple SREs, the observational period after the index PF was
extended to 3 months following the last observed SRE. To ensure that any HRU used to diagnose the SRE is included in the HRU burden for the SRE, a 14-day (2 week) period
immediately before the index PF was used to estimate any diagnostic HRU. The following calculation was used to estimate HRU: Estimate of HRU associated with PF=HRU recorded
during post-PF period+HRU during diagnosis period – HRU recorded during the baseline period. (a) Adjusted to allow for the diﬀerent lengths of the periods. The diagnosis period was
adjusted to allow for the diﬀerent lengths of the baseline and post-baseline periods. To calculate the HRU attributed to multiple SREs, for those observed at the same anatomical site and
within a 21-day window, the HRU was attributed to the index PF. For multiple SREs observed at the same anatomical site but outside the 21-day window, the expert panel attributed
HRU to the appropriate SRE. In the case of multiple SREs observed at diﬀerent anatomical sites on the same or diﬀerent days, the expert panel attributed HRU to the appropriate SRE.
HRU, healthcare resource utilisation; PF, pathologic fracture; SRE, skeletal-related event.
Table 1
Baseline demographics and disease characteristics of patients with pathologic fractures of long bones.
All countries
(N=118)
Austria
(n=25)
Czech
Republic
(n=18)
Finland
(n=8)
Greece
(n=8)
Poland
(n=28)
Portugal
(n=14)
Sweden
(n=9)
Switzerland
(n=8)
Mean age, years (SD) 65.7 (11.9) 62.9 (12.5) 66.3 (10.9) 74.5 (4.2) 68.9 (10.9) 62.8 (11.5) 61.5 (13.2) 75.8 (7.4) 66.9 (12.9)
Female, n (%) 64 (54.2) 14 (56.0) 10 (55.6) 2 (25.0) 5 (62.5) 17 (60.7) 8 (57.1) 2 (22.2) 6 (75.0)
Age group, n (%)
< 65 years 50 (42.4) 13 (52.0) 9 (50.0) 0 (0.0) 2 (25.0) 14 (50.0) 9 (64.3) 1 (11.1) 2 (25.0)
≥65 years 68 (57.6) 12 (48.0) 9 (50.0) 8 (100.0) 6 (75.0) 14 (50.0) 5 (35.7) 8 (88.9) 6 (75.0)
≥75 years 30 (25.4) 4 (16.0) 4 (22.2) 3 (37.5) 3 (37.5) 5 (17.9) 3 (21.4) 6 (66.7) 2 (25.0)
ECOG status, n (%)
0 8 (6.8) 1 (4.0) 1 (5.6) 1 (12.5) 1 (12.5) 2 (7.1) 0 (0.0) 1 (11.1) 1 (12.5)
1 29 (24.6) 3 (12.0) 5 (27.8) 1 (12.5) 2 (25.0) 8 (28.6) 4 (28.6) 4 (44.4) 2 (25.0)
2 28 (23.7) 2 (8.0) 6 (33.3) 2 (25.0) 3 (37.5) 8 (28.6) 1 (7.1) 2 (22.2) 4 (50.0)
3 18 (15.3) 1 (4.0) 4 (22.2) 2 (25.0) 0 (0.0) 8 (28.6) 2 (14.3) 1 (11.1) 0 (0.0)
4 3 (2.5) 0 (0.0) 1 (5.6) 0 (0.0) 0 (0.0) 1 (3.6) 0 (0.0) 1 (11.1) 0 (0.0)
Unknown 32 (27.1) 18 (72.0) 1 (5.6) 2 (25.0) 2 (25.0) 1 (3.6) 7 (50.0) 0 (0.0) 1 (12.5)
Primary tumour
diagnosis, n (%)
Breast cancer 44 (37.3) 11 (44.0) 10 (55.6) 2 (25.0) 1 (12.5) 8 (28.6) 5 (35.7) 1 (11.1) 6 (75.0)
Lung cancer 20 (16.9) 4 (16.0) 0 (0.0) 1 (12.5) 1 (12.5) 8 (28.6) 4 (28.6) 1 (11.1) 1 (12.5)
Prostate cancer 26 (22.0) 1 (4.0) 7 (38.9) 3 (37.5) 2 (25.0) 3 (10.7) 2 (14.3) 7 (77.8) 1 (12.5)
Multiple myeloma 28 (23.7) 9 (36.0) 1 (5.6) 2 (25.0) 4 (50.0) 9 (32.1) 3 (21.4) 0 (0.0) 0 (0.0)
SRE status, n (%)
Single 24 (20.3) 3 (12.0) 7 (38.9) 0 (0.0) 3 (37.5) 3 (10.7) 2 (14.3) 2 (22.2) 4 (50.0)
Multiple 94 (79.7) 22 (88.0) 11 (61.1) 8 (100.0) 5 (62.5) 25 (89.3) 12 (85.7) 7 (77.8) 4 (50.0)
Time since diagnosis of
bone metastases/
lesions, months
n 85 13 15 6 4 19 11 9 8
Mean (SD) 11.9 (25.9) 10.3 (15.7) 19.8 (36.4) 16.4 (26.3) 9.4 (11.2) 2.4 (5.8) 7.4 (18.7) 25.3 (50.5) 10.8 (16.7)
Median (Q1, Q3) 0.7 (0.0, 13.0) 3.1 (0.0,
15.4)
4.5 (0.0, 26.7) 7.1
(0.0,16.3)
8.2 (−0.18,
18.9)
0.0 (0.0,
1.3)
0.0 (0.0, 3.6) 0.7 (0.0,
31.5)
5.9 (0.5, 11.6)
Bone metastases sites, n
(%)
1–2 76 (64.4) 15 (60.0) 13 (72.2) 4 (50.0) 4 (50.0) 16 (57.1) 11 (78.6) 8 (88.9) 5 (62.5)
3–4 6 (5.1) 0 (0.0) 3 (16.7) 0 (0.0) 0 (0.0) 2 (7.1) 0 (0.0) 0 (0.0) 1 (12.5)
≥5 8 (6.8) 1 (4.0) 1 (5.6) 2 (25.0) 0 (0.0) 1 (3.6) 0 (0.0) 1 (11.1) 2 (25.0)
Missing 28 (23.7) 9 (36.0) 1 (5.6) 2 (25.0) 4 (50.0) 9 (32.1) 3 (21.4) 0 (0.0) 0 (0.0)
ECOG, Eastern Cooperative Oncology Group; Q, quartile; SD, standard deviation; SRE, skeletal-related event.
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had a single SRE (i.e. only the index PF) (79.7% [n=94] and 20.3%
[n=24], respectively; Table 1). However, in patients with PFs of other
bones, the proportions with multiple or single SREs were similar
(51.0% [n=123] and 49.0% [n=118], respectively; Table 2). SREs could
be classiﬁed as being linked or unlinked; subsequent linked SREs were
more frequent in patients with long bone PFs (73.4% of multiple SREs;
n=69) than in those with other bone PFs (47.2%; n=58). The most
common linked SREs were surgery to bone (long bones 42.4% [n=50];
other bones 6.6% [n=16]) and radiation to bone (long bones 18.6%
[n=22]; other bones 17.4% [n=42]).
3.3. Analyses of inpatient stays
The mean number of inpatient stays per PF increased from baseline
for both PF of long bones (1.2 [SD 1.2]) and other bones (0.8 [SD 1.2]
(Fig. 2a). The mean duration of inpatient stays also increased in both
groups (long bones 20.9 [SD 22.1] days; other bones 12.3 [SD 19.5]
days) (Fig. 2b). For individuals with long bone PFs, the greatest
increases in duration of stay per PF were reported in Portugal (32.1
[SD 19.8] days; n=14) and Finland (29.4 [SD 34.6] days; n=8). The
smallest increase was reported in Greece (5.8 [SD 8.3] days; n=8)
(Fig. 2b).
The types of hospital units that patients stayed in diﬀered according
to the type of fracture they experienced. The largest mean change from
baseline in the number of stays per PF of long bones occurred in
orthopaedic units (0.5 [SD 0.6]), but stays in oncology units and ‘other’
units (including trauma surgery, casualty units, cardiology units and
nursing units) also increased slightly (0.1 [SD 0.3]) and 0.1 [SD 0.8],
respectively). For individuals with PFs of other bones, the largest mean
increases from baseline in the number of inpatient stays per PF were
observed in internal medicine units (0.2 [SD 0.6]) and oncology units
(0.2 [SD 0.7]).
Table 2
Baseline demographics and disease characteristics of patients with pathologic fractures of bones other than long bones.
All countries
(N=241)
Austria
(n=22)
Czech
Republic
(n=33)
Finland
(n=30)
Greece
(n=32)
Poland
(n=30)
Portugal
(n=29)
Sweden
(n=27)
Switzerland
(n=38)
Mean age, years (SD) 64.5 (11.6) 63.6 (11.6) 64.8 (9.0) 64.6 (10.6) 63.3 (10.1) 63.0 (11.7) 62.9 (12.2) 62.7 (15.3) 69.1 (11.6)
Female, n (%) 119 (49.4) 11 (50.0) 20 (60.6) 16 (53.3) 12 (37.5) 17 (56.7) 16 (55.2) 7 (25.9) 20 (52.6)
Age group, n (%)
< 65 years 111 (46.1) 12 (54.5) 14 (42.4) 13 (43.3) 15 (46.9) 15 (50.0) 15 (51.7) 14 (51.9) 13 (34.2)
≥65 years 130 (53.9) 10 (45.5) 19 (57.6) 17 (56.7) 17 (53.1) 15 (50.0) 14 (48.3) 13 (48.1) 25 (65.8)
≥75 years 46 (19.1) 4 (18.2) 5 (15.2) 5 (16.7) 2 (6.3) 4 (13.3) 3 (10.3) 8 (29.6) 15 (39.5)
ECOG status, n (%)
0 16 (6.6) 4 (18.2) 2 (6.1) 0 (0.0) 4 (12.5) 0 (0.0) 1 (3.4) 0 (0.0) 5 (13.2)
1 68 (28.2) 7 (31.8) 15 (45.5) 7 (23.3) 7 (21.9) 10 (33.3) 4 (13.8) 2 (7.4) 16 (42.1)
2 69 (28.6) 0 (0.0) 10 (30.3) 14 (46.7) 16 (50.0) 15 (50.0) 3 (10.3) 2 (7.4) 9 (23.7)
3 19 (7.9) 0 (0.0) 3 (9.1) 3 (10.0) 2 (6.3) 4 (13.3) 0 (0.0) 3 (11.1) 4 (10.5)
4 3 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.1) 1 (3.3) 0 (0.0) 1 (3.7) 0 (0.0)
Unknown 66 (27.4) 11 (50.0) 3 (9.1) 6 (20.0) 2 (6.3) 0 (0.0) 21 (72.4) 19 (70.4) 4 (10.5)
Primary tumour
diagnosis, n (%)
Breast cancer 78 (32.4) 11 (50.0) 21 (63.6) 10 (33.3) 1 (3.1) 8 (26.7) 14 (48.3) 0 (0.0) 13 (34.2)
Lung cancer 23 (9.5) 3 (13.6) 0 (0.0) 9 (30.0) 3 (9.4) 3 (10.0) 4 (13.8) 0 (0.0) 1 (2.6)
Prostate cancer 42 (17.4) 1 (4.5) 9 (27.3) 7 (23.3) 3 (9.4) 1 (3.3) 5 (17.2) 10 (37.0) 6 (15.8)
Multiple myeloma 98 (40.7) 7 (31.8) 3 (9.1) 4 (13.3) 25 (78.1) 18 (60.0) 6 (20.7) 17 (63.0) 18 (47.4)
SRE status, n (%)
Single 118 (49.0) 8 (36.4) 25 (75.8) 3 (10.0) 22 (68.8) 17 (56.7) 7 (24.1) 19 (70.4) 17 (44.7)
Multiple 123 (51.0) 14 (63.6) 8 (24.2) 27 (90.0) 10 (31.3) 13 (43.3) 22 (75.9) 8 (29.6) 21 (55.3)
Time since diagnosis of
bone metastases,
months
n 142 14 30 26 7 12 23 10 20
Mean (SD) 12.2 (24.8) 6.8 (16.1) 15.8 (24.4) 15.8 (29.4) 2.2 (3.6) 1.6 (2.9) 9.1 (20.7) 15.5 (12.0) 17.6 (39.6)
Median (Q1, Q3) 0.5 (0.0, 11.4) 0.0 (0.0, 5.0) 1.0 (0.0, 22.6) 0.7 (0.0,
19.3)
0.2 (0.0,
5.6)
0.0 (0.0,
1.9)
0.7 (0.0, 6.1) 12.9 (8.4,
27.4)
0.4 (0.0, 15.8)
Bone metastases sites,
n (%)
1–2 108 (44.8) 11 (50.0) 26 (78.8) 11 (36.7) 7 (21.9) 9 (30.0) 23 (79.3) 7 (25.9) 14 (36.8)
3–4 19 (7.9) 3 (13.6) 2 (6.1) 9 (30.0) 0 (0.0) 1 (3.3) 0 (0.0) 2 (7.4) 2 (5.3)
≥5 16 (6.6) 1 (4.5) 2 (6.1) 6 (20.0) 0 (0.0) 2 (6.7) 0 (0.0) 1 (3.7) 4 (10.5)
Missing 98 (40.7) 7 (31.8) 3 (9.1) 4 (13.3) 25 (78.1) 18 (60.0) 6 (20.7) 17 (63.0) 18 (47.4)
ECOG, Eastern Cooperative Oncology Group; Q, quartile; SD, standard deviation; SRE, skeletal-related event.
Table 3
Site of fracture in patients with pathologic fractures of long bones.
Fracture site,
n (%)
All countries
(N=118)
Austria
(n=25)
Czech Republic
(n=18)
Finland
(n=8)
Greece
(n=8)
Poland
(n=28)
Portugal
(n=14)
Sweden
(n=9)
Switzerland
(n=8)
Femur 69 (58.5) 15 (60.0) 14 (77.8) 4 (50.0) 1 (12.5) 19 (67.9) 10 (71.4) 2 (22.2) 4 (50.0)
Humerus 38 (32.2) 8 (32.0) 4 (22.2) 3 (37.5) 3 (37.5) 7 (25.0) 4 (28.6) 7 (77.8) 2 (25.0)
Tibia 3 (2.5) 1 (4.0) 0 (0.0) 0 (0.0) 1 (12.5) 1 (3.6) 0 (0.0) 0 (0.0) 0 (0.0)
Radius 4 (3.4) 1 (4.0) 0 (0.0) 1 (12.5) 2 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Ulna 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.6) 0 (0.0) 0 (0.0) 0 (0.0)
Other 3 (2.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (12.5) 0 (0.0) 0 (0.0) 0 (0.0) 2 (25.0)
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3.4. Analyses of outpatient visits
Collectively, the mean number of outpatient visits per PF increased
in both groups. There was a larger increase in the number of visits per
event for patients with PFs of other bones (4.0 [SD 5.8]) than for those
with PFs of long bones (2.6 [SD 4.7]) (Fig. 3a). Compared with the
other countries in this study, Finland recorded the largest increase in
the mean number of outpatient visits per event (long bones 8.6 [SD
6.1]; n=8; other bones 6.8 [SD 6.1]; n=30). The smallest changes were
reported in Greece (0.9 [SD 3.3]; n=8) and Poland (0.9 [SD 3.2]; n=28)
Table 4
Site of fracture in patients with pathologic fractures of bones other than long bones.
Fracture site,
n (%)
All countries
(N=241)
Austria
(n=22)
Czech
Republic
(n=33)
Finland
(n=30)
Greece
(n=32)
Poland
(n=30)
Portugal
(n=29)
Sweden
(n=27)
Switzerland
(n=38)
Thoracic
vertebrae
97 (40.2) 5 (22.7) 13 (39.4) 8 (26.7) 18 (56.3) 12 (40.0) 16 (55.2) 12 (44.4) 13 (34.2)
Lumbar
vertebrae
56 (23.2) 2 (9.1) 7 (21.2) 5 (16.7) 7 (21.9) 13 (43.3) 9 (31.0) 5 (18.5) 8 (21.1)
Cervical
vertebrae
8 (3.3) 2 (9.1) 0 (0.0) 2 (6.7) 0 (0.0) 4 (13.3) 0 (0.0) 0 (0.0) 0 (0.0)
Ribs 29 (12.0) 5 (22.7) 3 (9.1) 11 (36.7) 3 (9.4) 0 (0.0) 0 (0.0) 2 (7.4) 5 (13.2)
Ilium 6 (2.5) 0 (0.0) 0 (0.0) 0 (0.0) 2 (6.3) 0 (0.0) 0 (0.0) 3 (11.1) 1 (2.6)
Sacrum 4 (1.7) 2 (9.1) 1 (3.0) 1 (3.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Clavicle 9 (3.7) 3 (13.6) 0 (0.0) 0 (0.0) 1 (3.1) 0 (0.0) 1 (3.4) 2 (7.4) 2 (5.3)
Ischium 3 (1.2) 0 (0.0) 1 (3.0) 0 (0.0) 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.6)
Pubis 6 (2.5) 2 (9.1) 2 (6.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.7) 1 (2.6)
Sternum 2 (0.8) 0 (0.0) 0 (0.0) 1 (3.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.6)
Scapula 2 (0.8) 0 (0.0) 1 (3.0) 0 (0.0) 0 (0.0) 1 (3.3) 0 (0.0) 0 (0.0) 0 (0.0)
Other 19 (7.9) 1 (4.5) 5 (15.2) 2 (6.7) 0 (0.0) 0 (0.0) 3 (10.3) 2 (7.4) 6 (15.8)
Table 5
Patients receiving bisphosphonate medication by dose frequency at baseline and in the post-SRE interval in patients with pathologic fractures of long bones.
All countries
(N=118)
Austria
(n=25)
Czech
Republic
(n=18)
Finland
(n=8)
Greece
(n=8)
Poland
(n=28)
Portugal
(n=14)
Sweden
(n=9)
Switzerland
(n=8)
Patients receiving
bisphosphonates at
baseline, n (%)
33 (28.0) 9 (36.0) 8 (44.4) 5 (62.5) 3 (37.5) 5 (17.9) 1 (7.1) 0 (0.0) 2 (25.0)
Disodium pamidronate 4 (3.4) 4 (14.3)
Ibandronic acid 6 (5.1) 3 (12.0) 2 (11.1) 1 (12.5)
Pamidronate disodium 1 (0.8) 1 (7.1)
Sodium clodronate 8 (6.8) 4 (22.2) 3 (37.5) 1 (3.6)
Zoledronic acid 14 (11.9) 6 (24.0) 2 (11.1) 2 (25.0) 2 (25.0) 2 (25.0)
Patients receiving
bisphosphonates after a
pathologic fracture, n (%)a
73 (61.9) 17 (68.0) 16 (88.9) 6 (75.0) 4 (50.0) 15 (53.6) 8 (57.1) 2 (22.2) 5 (62.5)
Bisphosphonate type and
dosing frequency, n (%)b
Clodronate disodium 2 (1.7) 2 (11.1)
Once a day 1 (0.8) 1 (5.6)
Other 1 (0.8) 1 (5.6)
Disodium pamidronate 19 (16.1) 1 (12.5) 13 (46.4) 5 (35.7)
Every 4 weeks 11 (9.3) 1 (12.5) 9 (32.1) 1 (7.1)
Once a month 6 (5.1) 4 (14.3) 2 (14.3)
Other 2 (1.7) 2 (14.3)
Ibandronic acid 8 (6.8) 5 (20.0) 2 (11.1) 1 (12.5)
Once a day 4 (3.4) 4 (16.0)
Every 4 weeks 4 (3.4) 1 (4.0) 2 (11.1) 1 (12.5)
Pamidronate disodium 1 (0.8) 1 (7.1)
Other 1 (0.8) 1 (7.1)
Sodium clodronate 16 (13.6) 1 (4.0) 8 (44.4) 4 (50.0) 3 (10.7)
Once a day 11 (9.3) 7 (38.9) 2 (25.0) 2 (7.1)
Other 5 (4.2) 1 (4.0) 1 (5.6) 2 (25.0) 1 (3.6)
Zoledronic acid 31 (26.3) 11 (44.0) 4 (22.2) 4 (50.0) 3 (37.5) 2 (14.3) 2 (22.2) 5 (62.5)
Once a day 1 (0.8) 1 (12.5)
Every 4 weeks 19 (16.1) 8 (32.0) 4 (22.2) 2 (25.0) 2 (14.3) 1 (11.1) 2 (25.0)
Once a month 5 (4.2) 1 (4.0) 1 (11.1) 3 (37.5)
Every 3 months 1 (0.8) 1 (12.5)
Other 5 (4.2) 2 (8.0) 2 (25.0) 1 (12.5)
SRE, skeletal-related event.
a Patients may have received more than one type of bisphosphonate and more than one dose regimen during the post-SRE period.
b For clarity, the type of bisphosphonate received after a pathologic fracture is shown in bold.
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for those with PFs of long bones. For individuals with PFs of other
bones, Poland had the smallest change in the mean number of
outpatient visits (0.8 [SD 1.7]; n=30).
The largest changes in the mean number of outpatient visits per PF
from baseline were in visits to radiation oncologists/radiotherapists
(long bones 1.0 [SD 2.5]; other bones 1.5 [SD 3.8]) and oncologists
(long bones 0.5 [SD 1.9]; other bones 0.8 [SD 2.3]). The increase in the
number of visits to orthopaedic surgeons was greater in patients with
PFs of long bones (0.3 [SD 0.7]) than in those with PFs of other bones
(0.1 [SD 0.3]). The number of visits to radiologists also increased, and
this change was greater in patients with PFs of other bones (0.6 [SD
1.7]) than in those with PFs of long bones (0.2 [SD 1.1]).
3.5. Analysis of day-care visits and emergency room visits
The increase in the mean number of day-care visits was smaller for
individuals with long bone PFs (0.8 [SD 2.7] than for those with other
bone PFs (1.4 [SD 3.6]). The mean number of emergency room visits
increased from baseline per PF of long bones (0.3 [SD 0.7]) and other
bones (0.2 [SD 0.9]).
3.6. Number and type of procedures
Overall, the number of procedures provided per event increased in
both PF groups (long bones 6.1 [SD 7.1]; other bones 5.9 [SD 6.6])
(Fig. 3b). Finland reported the greatest increase in the mean number of
procedures in patients with PFs of long bones (12.9 [SD 9.2]; n=8). In
individuals with PFs of other bones, the greatest increase was observed
in Austria (10.3 [SD 7.5]; n=22). For both fracture groups, the smallest
changes in the number of procedures were reported in Poland (long
bones 4.1 [SD 3.9]; n=28; other bones 2.7 [SD 2.7]; n=30). The largest
overall increase was seen in the use of external beam radiation (long
bones 2.1 [SD 3.9]; other bones 2.6 [SD 4.9]). In patients with PFs of
long bones, surgery to bone was also increased (0.5 [SD 0.5]). Notably,
the number of ‘other’ procedures increased in those with PFs of long
bones (2.3 [SD 3.9]); however, these encompassed a wide range of
Table 6
Patients receiving bisphosphonate medication by dose frequency at baseline and in the post-SRE interval in patients with pathologic fractures of bones other than long bones.
All countries
(N=241)
Austria
(n=22)
Czech
Republic
(n=33)
Finland
(n=30)
Greece
(n=32)
Poland
(n=30)
Portugal
(n=29)
Sweden
(n=27)
Switzerland
(n=38)
Patients receiving
bisphosphonates at
baseline, n (%)
61 (25.3) 4 (18.2) 10 (30.3) 10 (33.3) 2 (6.3) 12 (40.0) 5 (17.2) 9 (33.3) 9 (23.7)
Clodronate disodium 2 (0.8) 2 (6.1)
Disodium pamidronate 17 (7.1) 1 (4.5) 12 (40.0) 4 (13.8)
Ibandronic acid 1 (0.4) 1 (2.6)
Pamidronate disodium 6 (2.5) 6 (22.2)
Sodium clodronate 6 (2.5) 3 (9.1) 3 (10.0)
Zoledronic acid 29 (12.0) 3 (13.6) 5 (15.2) 7 (23.3) 2 (6.3) 1 (3.4) 3 (11.1) 8 (21.1)
Patients receiving
bisphosphonates after a
pathologic fracture, n (%)a
167 (69.3) 15 (68.2) 23 (69.7) 21 (70.0) 18 (56.3) 24 (80.0) 17 (58.6) 19 (70.4) 30 (78.9)
Bisphosphonate type and
dosing frequency, n (%)b
Alendronate sodium 1 (0.4) 1 (4.5)
Every week 1 (0.4) 1 (4.5)
Clodronate disodium 2 (0.8) 2 (6.1)
Once a day 1 (0.4) 1 (3.0)
Other 1 (0.4) 1 (3.0)
Disodium pamidronate 42 (17.4) 4 (18.2) 23 (76.7) 9 (31.0) 6 (15.8)
Once a day 1 (0.4) 1 (2.6)
Every 4 weeks 24 (10.0) 2 (9.1) 20 (66.7) 2 (5.3)
Once a month 8 (3.3) 3 (10.0) 2 (6.9) 3 (7.9)
Other 9 (3.7) 2 (9.1) 7 (24.1)
Ibandronic acid 7 (2.9) 1 (4.5) 2 (6.1) 1 (3.4) 1 (3.7) 2 (5.3)
Once a day 3 (1.2) 1 (3.0) 1 (3.4) 1 (3.7)
Every 4 weeks 2 (0.8) 1 (4.5) 1 (3.0)
Once a month 1 (0.4) 1 (2.6)
Other 1 (0.4) 1 (2.6)
Pamidronate disodium 15 (6.2) 1 (3.4) 14 (51.9)
Every 4 weeks 10 (4.1) 1 (3.4) 9 (33.3)
Once a month 3 (1.2) 3 (11.1)
Every 3 months 2 (0.8) 2 (7.4)
Sodium clodronate 15 (6.2) 9 (27.3) 5 (16.7) 1 (3.3)
Once a day 13 (5.4) 7 (21.2) 5 (16.7) 1 (3.3)
Other 2 (0.8) 2 (6.1)
Zoledronic acid 91 (37.8) 10 (45.5) 10 (30.3) 18 (60.0) 18 (56.3) 7 (24.1) 5 (18.5) 23 (60.5)
Once a day 4 (1.7) 1 (3.0) 1 (3.3) 1 (3.1) 1 (2.6)
3–4 times a week 1 (0.4) 1 (3.3)
Every week 1 (0.4) 1 (3.3)
Every 4 weeks 45 (18.7) 7 (31.8) 8 (24.2) 3 (10.0) 14 (43.8) 3 (10.3) 2 (7.4) 8 (21.1)
Once a month 18 (7.5) 2 (6.7) 1 (3.1) 1 (3.4) 1 (3.7) 13 (34.2)
Every 3 months 3 (1.2) 2 (6.7) 1 (2.6)
Other 19 (7.9) 3 (13.6) 1 (3.0) 8 (26.7) 2 (6.3) 3 (10.3) 2 (7.4)
SRE, skeletal-related event.
a Patients may have received more than one type of bisphosphonate and more than one dose regimen during the post-SRE period.
b For clarity, the type of bisphosphonate received after a pathologic fracture is shown in bold.
J.-J. Body et al. Journal of Bone Oncology 5 (2016) 185–193
190
diagnostic procedures, none of which showed a large change when
considered alone. In patients with PFs of other bones, the number of
‘other’ procedures also increased from baseline (1.7 [SD 3.3]), and use
of computerised tomography also increased (0.6 [SD 1.1]).
4. Discussion
This is the ﬁrst study to capture real-world changes in HRU
associated with PFs of long bones and, separately, also PFs of other
Fig. 2. Mean change from baseline in (a) the number and (b) the duration of inpatient stays per SRE. Data are shown as mean+standard deviation. n is the number of patients enrolled
from each country with PF of long bones/PF of other bones (and the overall number is given under the ﬁrst two bars). PF, pathologic fracture; SRE, skeletal-related event.
Fig. 3. Mean change from baseline in the number of (a) outpatient visits and (b) procedures per SRE. Data are shown as mean+standard deviation. n is the number of patients enrolled
from each country with PF of long bones/PF of other bones (and the overall number is given under the ﬁrst two bars). PF, pathologic fracture; SRE, skeletal-related event.
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bones. Overall, PFs were associated with considerable HRU owing to
increases in the number of inpatient and outpatient visits, duration of
inpatient stays, and number of procedures required.
Over the follow-up period of approximately 3 months, the mean
number of inpatient stays and outpatient visits per PF increased in
both groups. A multicentre, observational European study conducted
over an 18-month period also found that the mean number of inpatient
stays and outpatient visits increased in patients with PFs (range 0.4–
0.5 increase in inpatient stays per PF; range 1.9–3.1 increase in
outpatient visits per PF) [16]. An observational study in Spain revealed
that a large proportion of patients with PFs secondary to solid tumours
required hospital stays (40–60%) and outpatient visits (67–70%) [13].
In our study, the mean duration of inpatient stays also increased as
a result of PF in both the long bone and other bone groups. In a
previous retrospective-prospective study of HRU associated with SREs
in four European countries, PFs were found to be associated with a
considerable number of inpatient stays, with a duration ranging from
19 to 22 days [16], similar to the durations of inpatient stays that were
observed in our study. Inpatient stays appear to be a substantial driver
of overall HRU and therefore are likely to contribute considerably to
the costs associated with PFs. In addition, a large study in Spain
demonstrated that the mean length of hospital stay following the ﬁrst
admission for PF was substantial for those with breast, lung or prostate
cancer (12–20 days) [19]. The results of our study indicate for the ﬁrst
time that the increase in the number and duration of inpatient stays is
generally much higher for PFs of long bones than for PFs of other
bones. This may be due in part to patients with long bone PFs requiring
complicated and lengthy rehabilitation, including surgery and phy-
siotherapy. Owing to limited resources for the care of patients with
cancer and fractures in general hospitals, these individuals may have to
receive inpatient care at specialised units, which will further increase
the HRU costs associated with PFs of the long bones.
It has previously been shown that patients who experience one SRE
are more likely to experience subsequent events [20,21]. A retro-
spective analysis of patients with prostate cancer found that skeletal
morbidity (including PFs and bone pain) was higher in patients who
had experienced a SRE than in those with no history of SREs [22]. Our
study found that the majority of patients with PFs of long bones
experienced multiple SREs. In some pivotal clinical trials, multiple
SREs were not recorded because all SREs that occurred within a 21-day
window were counted as a single event [23,24]. Our study used
retrospective real-world data, and may therefore reﬂect clinical practice
more closely than clinical trials. The treatment of multiple SREs is
likely to require more outpatient hospital visits and inpatient stays than
the treatment of a single SRE, and this may also contribute to the
greater increases in HRU observed for long bone PFs compared with
those aﬀecting other bones. The proportion of patients receiving
bisphosphonates increased from baseline at similar levels during the
duration of this study for patients with PFs of long bones and those
with PFs of other bones. The fact that some patients were already
receiving bisphosphonate treatment yet still experienced a PF indicates
that further treatment optimisation with bone-targeted agents (BTAs)
and new antineoplastic agents may be required to minimise the
frequency of PFs, and thereby HRU.
PFs aﬀect a large proportion of patients with advanced cancers and
require a considerable amount of healthcare resources for their
treatment; this means that PFs result in substantial costs [13,15].
Another multinational European study of patients with solid tumours
and multiple myeloma estimated that the mean costs associated with
each individual PF ranged from €1000 to €7000 for vertebral fractures
and from €1700 to €3200 for non-vertebral fractures [15]. In Spain
and Belgium, the mean HRU cost per PF has also been reported to be
high (€3209 and €7087 for non-vertebral fractures and €5015 and
€6968 for vertebral fractures in Spain and Belgium, respectively)
[13,25]. In Portugal, one of the countries included in our analysis,
the estimated annual cost of PFs per patient was €8730 [26]. The costs
associated with surgery to bone and radiation to bone are also
substantial [15] and were the linked SREs with largest increases from
baseline in our study.
A strength of this study is the ability to distinguish between the
diﬀerent PFs because HRU is diﬀerent for each fracture type; long bone
fractures are rarely asymptomatic and will have HRU requirements
that are diﬀerent from those of other bone fractures. The main
limitation of our study was the low number of patients with PF of
long bones identiﬁed in each country, reﬂecting a low incidence of this
fracture type in patients with cancer. One study of patients with
advanced breast cancer found that the incidence of long bone fracture
was half that of other fracture types [27]. Furthermore, the use of bone-
targeted agents in routine clinical practice may have reduced the
incidence of SREs overall, as seen in clinical trials [9,28–30].
However, the baseline demographics of patients from countries with
low recruitment were generally consistent with those of the other
countries in the study.
5. Conclusion
This is the ﬁrst study to diﬀerentiate between the HRU attributed to
PFs of long bones and to those aﬀecting other bones. Both fracture
types were associated with increases from baseline in the mean number
of inpatient and outpatient stays, and visits to day care centres and
emergency rooms. The mean number of procedures was also increased
from baseline for both fracture types. The number of SREs can be
reduced by using bone-targeted agents such as bisphosphonates
[9,28,31], radiopharmaceuticals [32] or denosumab [29,30,33], or
new antineoplastic agents for prostate cancer such as enzalutamide
[34] and abiraterone acetate [35]. Combining these new antineoplastic
agents with bone-targeted agents may lead to greater reductions in
HRU in patients with advanced cancer.
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